Pharma & Bio
Business·Industry
Rokit and AprilBio Hit Daily Price Limit...HanAll Jumps on Its Own Catalyst [K-Bio Pulse]
The biotech and healthcare sector experienced a rare surge in positive momentum on June 24, driven by optimism surrounding the 2026 BIO International Convention, also known as BIO USA, the world’s lar…
Business·Industry
Rocket, Hanol, and AprilSoar Amid Positive Sentiment from 'Bio USA'… What’s Behind It? [Bio Insight]
On the 24th, the biotech and healthcare sector saw a rare upswing, driven by the impact of the “2026 Bio International Convention (Bio USA),” the world’s largest biotech exhibition.
KOSDAQ Stock In…
Technology
"From Dreams and Stories to Financial Statements"... The Stock Market Proves the Criteria for Leading K-Bio Stocks [Bio Companies with Solid Numbers, Part 1]
As the domestic stock market has shifted to a performance-driven market centered on semiconductors, attention is also growing in the pharmaceutical, biotech, and healthcare sectors, particularly towar…
Lifestyle
A Rush to Develop Mesenchymal Stem Cell-Based Curative Treatments for Osteoarthritis... What Are the Key Points?
As the global population continues to age, the number of patients with knee osteoarthritis is rapidly increasing. Consequently, active research is underway in South Korea to develop a disease-modifyin…
Lifestyle
Kang Se-il, CEO of S-Bio CO., LTD.: “New Parkinson’s Drug Demonstrates Competitive Edge in Treating More Severely Affected Patients Compared to U.S. Competitors”
S.Biomedics Co., Ltd.(304360)S.Biomedics Co., Ltd. has released the 24-month follow-up results from the Phase 1/2a clinical trial of its Parkinson’s disease cell therapy “TED-A9” and expressed confide…
KOSDAQ
BIO USA Optimism Boosts BL Pharmtech … D&D Pharmatech Falls on Convertible Bond Conversion [K-Bio Pulse]
South Korea’s pharmaceutical and biotech sector was driven by expectations surrounding BIO USA 2026, the world’s largest global biotech partnering event, on July 23. BL Pharmtech surged on hopes for b…
KOSDAQ
BL Pharmtech Rises on BIO USA Optimism… D&D Pharmatech Inc. Falls on Convertible Bond Conversion [Bio Spotlight]
On the 23rd, the domestic pharmaceutical and biotech sector was driven by market sentiment fueled by anticipation surrounding the global biotech partnering event “BIO USA 2026.” BL Pharmtech posted st…
Lifestyle
[BioUSA] Park Tae-yong, Vice President of Galax: “Conducting Joint Research on AI-Based New Drugs with AstraZeneca on the Premise of Technology Transfer”
Park Tae-yong, Vice President of Galax, is delivering a presentation on the 22nd at the “NOVA Global Connect 2026” event, co-hosted by the Korea Health Industry Development Institute (KHIDI) and Astra…
Technology
Lee Seul-ki, CEO of D&D Pharmatech Inc.: “J.P. Morgan reached out first… We will begin clinical trials for a new antifibrotic drug for liver cirrhosis next year”
D&D Pharmatech Inc.(347850)has entered into full-scale technology transfer negotiations following the release of tissue biopsy results for DD01, a candidate drug for metabolic and alcoholic steatohepa…
Business·Industry
Chip Rally Deepens KOSDAQ Biotech Slump [K-Bio Pulse]
On June 22, South Korea’s benchmark KOSPI market witnessed a symbolic changing of the guard: Samsung Electronics, which had held the No. 1 spot by market capitalization for 24 years, ceded the throne …